Cardlytics (NASDAQ:CDLX) Given a $43.00 Price Target at JPMorgan Chase & Co.

Share on StockTwits

Cardlytics (NASDAQ:CDLX) has been assigned a $43.00 price target by equities researchers at JPMorgan Chase & Co. in a note issued to investors on Friday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 36.33% from the stock’s current price.

Several other research analysts have also weighed in on CDLX. William Blair began coverage on shares of Cardlytics in a research note on Monday, July 1st. They set an “outperform” rating for the company. ValuEngine lowered shares of Cardlytics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. KeyCorp boosted their target price on shares of Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Friday, May 10th. Zacks Investment Research lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Bank of America restated a “buy” rating and set a $32.00 target price (up from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Cardlytics presently has an average rating of “Buy” and an average target price of $33.29.

Shares of CDLX stock traded down $1.36 during trading hours on Friday, hitting $31.54. The company’s stock had a trading volume of 580,883 shares, compared to its average volume of 248,975. The stock has a 50 day simple moving average of $27.77. The stock has a market cap of $726.53 million, a PE ratio of -14.74 and a beta of 1.76. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.37 and a current ratio of 2.37. Cardlytics has a 12-month low of $9.80 and a 12-month high of $34.30.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 64.83%. The business had revenue of $48.73 million during the quarter, compared to analysts’ expectations of $43.77 million. During the same period in the prior year, the business earned ($0.21) earnings per share. The company’s quarterly revenue was up 37.0% compared to the same quarter last year. Research analysts expect that Cardlytics will post -1.12 EPS for the current year.

In other Cardlytics news, Director Bryce Youngren sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $23.04, for a total value of $2,304,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Scott D. Grimes sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $23.76, for a total value of $95,040.00. The disclosure for this sale can be found here. Insiders have sold a total of 506,715 shares of company stock valued at $13,244,948 in the last quarter. Company insiders own 21.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDLX. Bank of Montreal Can raised its position in shares of Cardlytics by 16,371.4% during the 2nd quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after acquiring an additional 1,146 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Cardlytics in the second quarter worth $60,000. Rockefeller Capital Management L.P. bought a new position in shares of Cardlytics in the second quarter worth $85,000. Acadian Asset Management LLC bought a new position in shares of Cardlytics in the second quarter worth $161,000. Finally, Gamco Investors INC. ET AL bought a new position in shares of Cardlytics in the first quarter worth $256,000. Hedge funds and other institutional investors own 71.09% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Further Reading: What does it mean to hold a stock in street name?

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.